Park Avenue Securities LLC Buys 4,739 Shares of DexCom, Inc. (NASDAQ:DXCM)

Park Avenue Securities LLC increased its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 35.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,086 shares of the medical device company's stock after buying an additional 4,739 shares during the quarter. Park Avenue Securities LLC's holdings in DexCom were worth $1,235,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Geode Capital Management LLC raised its holdings in shares of DexCom by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company's stock valued at $775,256,000 after acquiring an additional 56,094 shares in the last quarter. Norges Bank purchased a new position in DexCom in the fourth quarter valued at about $385,367,000. Northern Trust Corp grew its stake in DexCom by 22.2% in the fourth quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock valued at $322,454,000 after purchasing an additional 753,857 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in DexCom by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company's stock valued at $219,716,000 after purchasing an additional 91,051 shares during the last quarter. Finally, Artisan Partners Limited Partnership grew its stake in DexCom by 12.2% in the fourth quarter. Artisan Partners Limited Partnership now owns 1,853,565 shares of the medical device company's stock valued at $144,152,000 after purchasing an additional 201,181 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Stock Performance

NASDAQ:DXCM traded down $0.86 during mid-day trading on Friday, reaching $81.99. 2,904,075 shares of the stock were exchanged, compared to its average volume of 4,350,358. The company has a 50 day simple moving average of $78.50 and a 200-day simple moving average of $79.32. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $117.91. The stock has a market capitalization of $32.15 billion, a P/E ratio of 57.34, a P/E/G ratio of 2.30 and a beta of 1.46. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The business had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The firm's quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.32 earnings per share. Analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on DXCM shares. Wall Street Zen upgraded DexCom from a "hold" rating to a "buy" rating in a research note on Friday, June 6th. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Cfra Research upgraded DexCom to a "hold" rating in a research report on Friday, March 21st. Mizuho began coverage on DexCom in a research report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 target price on the stock. Finally, Citigroup reissued a "buy" rating and issued a $102.00 price target (up from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Four analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $98.32.

Insider Transactions at DexCom

In related news, EVP Michael Jon Brown sold 10,000 shares of DexCom stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $84.28, for a total transaction of $842,800.00. Following the completion of the sale, the executive vice president now owns 95,602 shares of the company's stock, valued at approximately $8,057,336.56. This trade represents a 9.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Sadie Stern sold 6,184 shares of DexCom stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the sale, the executive vice president now directly owns 109,621 shares of the company's stock, valued at approximately $9,329,843.31. The trade was a 5.34% decrease in their position. The disclosure for this sale can be found here. Insiders sold 16,536 shares of company stock valued at $1,393,876 over the last quarter. Company insiders own 0.32% of the company's stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.